ACRO Biomedical Reports No Revenue for Q2 2025, Increases Losses and Operating Expenses

ACRO Biomedical Co., Ltd. reported its financial results for the second quarter of 2025, revealing a continued lack of revenue generation. The company reported no revenue for both the three and six months ended June 30, 2025, consistent with the same periods in the previous year. Operating expenses for the second quarter increased to $13,614, up from $9,086 in the same quarter of 2024, primarily due to higher professional fees associated with maintaining its public company status. The net loss for the quarter was $15,562, compared to a loss of $10,143 in the prior year, reflecting a 54% increase in losses year-over-year.

In terms of financial position, ACRO Biomedical's total assets rose to $53,277,000 as of June 30, 2025, compared to $31,974,000 at the end of 2024. This increase was largely driven by a significant rise in current assets, which jumped from $5,076,000 to $39,626,000, primarily due to prepaid expenses. However, total liabilities also increased, reaching $370,797,000, up from $326,946,000, indicating a growing financial burden. The company's stockholders' deficit widened to $317,520, compared to $294,972 at the end of the previous fiscal year.

Operationally, ACRO Biomedical has not made any sales since December 31, 2022, and has not developed any new products from its research and development activities. The company continues to rely on advances from a minority stockholder for funding, which amounted to $116,065 in the first half of 2025, compared to $20,392 in the same period of 2024. The lack of revenue and reliance on external funding raise concerns about the company's ability to sustain operations moving forward.

The company has indicated that it faces significant challenges, including the impact of COVID-19 restrictions in China, which have affected its customer base and sales potential. Additionally, ACRO Biomedical's common stock is currently traded on the OTC Market Group’s Pink Limited Market, limiting its marketability and raising concerns about liquidity. The company has acknowledged that it may not be able to continue as a going concern if it cannot generate revenue or secure additional funding.

Looking ahead, ACRO Biomedical has expressed uncertainty regarding its ability to develop marketable products or generate significant revenue. The company plans to explore potential funding through equity financing arrangements but currently lacks any agreements or orders for products. The management has highlighted the need for substantial improvements in its operational and financial strategies to navigate the ongoing challenges and achieve future growth.